Most recently, staging of CKD with cystatin C-eGFR has been proposed as a more accurate predictor of negative cardiovascular outcomes after TAVR than creatinine based eGFR, given the influence of muscle mass in creatinine eGFR [34], which would be of especial relevance in the risk stratification of sarcopenic elderly patients. The gene discussed is CST3; the disease is chronic kidney disease.